company background image
SGT logo

Seagen DB:SGT Stock Report

Last Price

€208.60

Market Cap

€39.6b

7D

3.4%

1Y

74.0%

Updated

14 Dec, 2023

Data

Company Financials +

Seagen Inc.

DB:SGT Stock Report

Market Cap: €39.6b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SGT Stock Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. More details

SGT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Earnings are forecast to grow 71.83% per year

Risk Analysis

No risks detected for SGT from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Seagen Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€487.3m

Merck KGaA

XTRA:MRK

€58.5b

Bayer

XTRA:BAYN

€22.9b

Price History & Performance

Summary of share price highs, lows and changes for Seagen
Historical stock prices
Current Share PriceUS$208.60
52 Week HighUS$212.00
52 Week LowUS$116.78
Beta0.32
1 Month Change6.27%
3 Month Change6.92%
1 Year Change74.04%
3 Year Change28.86%
5 Year Change318.88%
Change since IPO6,694.79%

Recent News & Updates

Recent updates

Shareholder Returns

SGTDE BiotechsDE Market
7D3.4%3.1%-0.5%
1Y74.0%-6.0%15.5%

Return vs Industry: SGT exceeded the German Biotechs industry which returned -23.2% over the past year.

Return vs Market: SGT exceeded the German Market which returned 4.8% over the past year.

Price Volatility

Is SGT's price volatile compared to industry and market?
SGT volatility
SGT Average Weekly Movement2.0%
Biotechs Industry Average Movement9.3%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: SGT has not had significant price volatility in the past 3 months.

Volatility Over Time: SGT's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19973,256David Epsteinwww.seagen.com

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases.

Seagen Inc. Fundamentals Summary

How do Seagen's earnings and revenue compare to its market cap?
SGT fundamental statistics
Market cap€39.61b
Earnings (TTM)-€688.56m
Revenue (TTM)€2.11b

18.8x

P/S Ratio

-57.5x

P/E Ratio

Is SGT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SGT income statement (TTM)
RevenueUS$2.30b
Cost of RevenueUS$2.13b
Gross ProfitUS$171.59m
Other ExpensesUS$921.81m
Earnings-US$750.22m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.98
Gross Margin7.46%
Net Profit Margin-32.61%
Debt/Equity Ratio0%

How did SGT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/14 04:08
End of Day Share Price 2023/12/13 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Seagen Inc. is covered by 30 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarBerenberg
George FarmerBMO Capital Markets Equity Research
Geoffrey MeachamBofA Global Research